{"id":"W84221740","doi":"10.1182/blood.v122.21.661.661","title":"Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Polycythemia vera; Essential thrombocythemia; Phases of clinical research; Gastroenterology; Clinical trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001205184,0.0005964803,0.001243881,0.0003271991,0.0002348604,0.0006537361,0.0004202718,0.0007372887,0.001669792],"category_scores_gemma":[0.0007906269,0.0002555806,0.001497375,0.0003237061,0.0003949875,0.0005350831,0.0002379207,0.001571482,0.0004238969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000663679,"about_ca_system_score_gemma":0.0006066554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005900265,"about_ca_topic_score_gemma":0.001615837,"domain_scores_codex":[0.9995868,0.0001639068,0.00004288264,0.0000815649,0.00005149996,0.00007341166],"domain_scores_gemma":[0.9994295,0.000092669,0.0001346508,0.00004770373,0.00003497043,0.0002604485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6298165,0.01626503,0.05613522,0.0007198908,0.002447484,0.000960637,0.0002181669,0.003746497,0.04178223,0.0002628479,0.004730825,0.2429147],"study_design_scores_gemma":[0.2193548,0.5080525,0.244121,0.0001436406,0.003008933,0.002057101,0.0001181214,0.005244837,0.01263346,0.0003945989,0.00475031,0.0001206899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935451,0.003228918,0.0002278232,0.0002123315,0.00005718358,0.000286437,0.0009162951,0.00005130907,0.001474636],"genre_scores_gemma":[0.9969947,0.0006002729,0.0002891772,0.0002420291,0.00005020528,0.0001193901,0.001266977,0.000004595373,0.0004327869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001669792,"threshold_uncertainty_score":0.006373763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00992980083170512,"score_gpt":0.2635124977117351,"score_spread":0.25358269688003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}